QCLS Q/C Technologies, Inc.
Distress ·
Q/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning.
The former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised.
TNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers.
Nasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market.
TNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $3.5 million | $3.4 million |
| Net income (loss) | -$11.6 million | -$23.4 million |
| Cash from operations | -$9.1 million | -$9.0 million |
| Cash and equivalents | $986,996 | $173,154 |
| Short-term investments | $14.8 million | $8.3 million |
Our latest story on this, dated Nov 14, 2025: "Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 26, 2025: "Q/C Technologies, formerly TNF Pharmaceuticals, starts trading as QCLS". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 14, 2025: "Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report". The story links the filing or release it is based on. Read the story.
Q/C Technologies, Inc. trades under the ticker QCLS on NASDAQ.
Q/C Technologies, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A8D.
The SEC Central Index Key (CIK) for Q/C Technologies, Inc. is 1321834. Its filings are on SEC EDGAR.
8,189,838 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Q/C Technologies, Inc. under United States.
Our directory classifies Q/C Technologies, Inc. as: Mixed biopharma / computing infrastructure. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Q/C Technologies, Inc. is US62856X3008.
aibio.space lists Q/C Technologies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Q/C Technologies, Inc. reported a net loss of $11.6 million for the fiscal year ended Dec 31, 2025, and used $9.1 million of cash in operations, per its annual report to the SEC.
$3.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$11.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,3.03,5.02,5.03,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio